Increased generation of platelet-derived microparticles following percutaneous transluminal coronary angioplasty

Increased generation of platelet-derived microparticles following percutaneous transluminal coronary angioplasty

Platelet-derived microparticles that are produced during
platelet activation bind to traumatized endothelium. Such
endothelial injury occurs during percutaneous transluminal
coronary angioplasty. Approximately 20% of these patients
subsequently develop restenosis, although this is
improved by treatment with the anti-platelet glycoprotein
IIb/IIIa receptor drug abciximab. As platelet activation
occurs during angioplasty, it is likely that platelet-derived microparticles may be produced and hence contribute to restenosis. This study population consisted of 113
angioplasty patients, of whom 38 received abciximab.
Paired peripheral arterial blood samples were obtained
following heparinization and subsequent to all vessel
manipulation. Platelet-derived microparticles were
identified using an anti-CD61 (glycoprotein IIIa)
fluorescence-conjugated antibody and flow cytometry.
Baseline clinical characteristics between patient groups
were similar. The level of platelet-derived microparticles
increased significantly following angioplasty in the group
without abciximab (paired t test, P 0.019). However, there
was no significant change in the level of platelet-derived
microparticles following angioplasty in patients who
received abciximab, despite requiring more complex
angioplasty procedures. In this study, we have
demonstrated that the level of platelet-derived
microparticles increased during percutaneous transluminal
coronary angioplasty, with no such increase with abciximab treatment. The increased platelet-derived microparticles may adhere to traumatized endothelium,contributing to re-occlusion of the arteries, but this remains to be determined.

Files associated with this item cannot be displayed due to copyright restrictions.